GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
GES-13 beta-lactamase, a novel GES variant possessing Lys-104 and Asn-170, was identified in Pseudomonas aeruginosa. bla(GES-13) was the single gene cassette of a class 1 integron probably located in the chromosome. GES-13 efficiently hydrolyzed broad-spectrum cephalosporins and aztreonam. Imipenem was a potent inhibitor of GES-13 but was not hydrolyzed at measurable rates.
Kotsakis
S D
SD
Laboratory of Bacteriology, Hellenic Pasteur Institute, Athens, Greece.
Papagiannitsis
C C
CC
Tzelepi
E
E
Legakis
N J
NJ
Miriagou
V
V
Tzouvelekis
L S
LS
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001398:Aztreonam / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D014644:Genetic Variation; D006801:Humans; D032023:Integrons / Q000235:genetics; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D011552:Pseudomonas Infections / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics; D017422:Sequence Analysis, DNA; D001618:beta-Lactamases / Q000096:biosynthesis / Q000235:genetics; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D047090:beta-Lactams; D001618:beta-Lactamases; D001398:Aztreonam